Reproductive Pattern of Parous Women and the Risk of Cancer in Later Life.

Cancers (Basel)

Aberdeen Centre for Women's Health Research, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen AB25 2ZL, UK.

Published: July 2021

AI Article Synopsis

  • A study of 6,430 parous women in northeast Scotland found that the number of pregnancies does not significantly impact cancer risk compared to women with one pregnancy.* -
  • Women with cumulative pregnancy times between 50-150 weeks showed no increased cancer risk compared to those with 50 weeks or less.* -
  • Having a first delivery at a younger age is linked to lower odds of certain cancers, while an inter-pregnancy interval longer than three years is associated with a higher risk of any cancer diagnosis.*

Article Abstract

We assessed the risk of any and site-specific cancers in a case-control study of parous women living in northeast Scotland in relation to: total number of pregnancies, cumulative time pregnant, age at first delivery and interpregnancy interval. We analysed 6430 women with cancer and 6430 age-matched controls. After adjustment for confounders, women with increasing number of pregnancies had similar odds of cancer diagnosis as women with only one pregnancy. The adjusted odds of cancer diagnosis were no higher in women with cumulative pregnancy time 50-150 weeks compared to those pregnant ≤ 50 weeks. Compared with women who had their first delivery at or before 20 years of age, the adjusted odds ratio (AOR) among those aged 21-25 years was 0.81, 95% CI 0.74, 0.88; 26-30 years AOR 0.77, 95% CI 0.69, 0.86; >30 years AOR 0.63, 95% CI 0.55, 0.73. After adjustment, the odds of having any cancer were higher in women who had an inter-pregnancy interval >3 years compared to those with no subsequent pregnancy (AOR 1.17, 95% CI 1.05, 1.30). Older age at first pregnancy was associated with increased risk of breast and gastrointestinal cancer, and reduced risk of invasive cervical, carcinoma in situ of the cervix and respiratory cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345127PMC
http://dx.doi.org/10.3390/cancers13153731DOI Listing

Publication Analysis

Top Keywords

odds cancer
12
women
8
parous women
8
number pregnancies
8
cancer diagnosis
8
adjusted odds
8
higher women
8
weeks compared
8
years aor
8
cancer
7

Similar Publications

Patient characteristics in relation to opioid exposure in a chronic non-cancer pain population.

Scand J Pain

January 2024

Department of Clinical Sciences Malmö, Center for Primary Health Care Research, Lund University, Jan Waldenströms Gata 35, 202 13 Malmö, Sweden.

Objectives: The efficacy of long-term opioid therapy (LTOT) in treating patients with chronic non-cancer pain (CnCP) is questionable, and the potential risks of adverse effects are well established. The aims were as follows: (1) compare characteristics in patients exposed to LTOT vs non-exposed. (2) Regarding opioid-exposed patients, describe characteristics of patients with risk factors for opioid use disorder or overdose in relation to opioid dosage.

View Article and Find Full Text PDF

Skin cancer associated with calcineurin inhibitors treatment: analysis of FAERS database.

Expert Opin Drug Saf

December 2024

Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

Background: Several studies have indicated a potential link between calcineurin inhibitors (CNIs) and skin cancers. However, comprehensive evidence of CNIs-induced skin cancers remains lacking.

Research Design And Methods: We conducted an observational retrospective pharmacovigilance study utilizing the FAERS database to identify potential risk signals associated with skin cancers with CNIs treatment, encompassing data from its inception to the third quarter of 2023.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitor (ICI) therapy has revolutionized cancer treatment but is associated with fulminant type 1 diabetes mellitus (FT1DM). Our study aims to investigate the association between ICI therapy and FT1DM using the FDA Adverse Event Reporting System (FAERS) database.

Methods: We conducted a retrospective analysis from the first quarter of 2004 to the first quarter of 2023.

View Article and Find Full Text PDF

Background: Capecitabine, a prodrug of 5-fluorouracil, is extensively utilized for the treatment of metastatic breast cancer, colorectal cancer, and gastric cancer. Nevertheless, there exist limitations in comprehending adverse reactions (AEs) in clinical practice. In this study, we investigated the distribution of AEs associated with capecitabine and explored potential rare adverse reactions by mining the Food and Drug Administration Adverse Event Reporting System (FAERS).

View Article and Find Full Text PDF

Comprehensive analysis of risk factors associated with submucosal invasion in patients with early-stage gastric cancer.

World J Gastroenterol

December 2024

Department of Gastroenterology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou 450000, Henan Province, China.

Background: Submucosal invasion in early-stage gastric cancer (GC) is a critical determinant of prognosis and treatment strategy, significantly influencing the risk of lymph node metastasis and recurrence. Identifying risk factors associated with submucosal invasion is essential for optimizing patient management and improving outcomes.

Aim: To comprehensively analyze clinical, imaging, and endoscopic characteristics to identify predictors of submucosal invasion in patients with early-stage differentiated GC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!